Overexpression of caveolin-1 and -2 in cell lines and in human samples of inflammatory breast cancer
Inflammatory breast cancer (IBC) is the most aggressive form of locally advanced breast cancer (LABC). The IBC phenotype is characterized by an infiltrative growth pattern, increased (lymph)angiogenesis and the propensity to invade dermal lymphatics. In pancreatic cancer, interactions between caveolin-1 and RhoC GTPase, a key molecule in causing the IBC phenotype, regulate tumour cell motility and invasion. In this study we sought to investigate the role of caveolin-1 and -2 in IBC cell lines and in human IBC samples.
Differential methylation techniques identified the methylation status of the caveolin-1 and -2 promoters in human mammary epithelial cells (HMECs) and the SUM149 cell line. In cell line experiments, caveolin-1 and -2 mRNA and protein expression were compared in HMECs, MCF10A, the SUM102 non-IBC cell lines and 2 IBC cell lines (SUM149 and SUM190). Furthermore, caveolin-1 and -2 mRNA and protein expression were compared in human IBC and non-IBC samples using cDNA microarray, real-time qRT-PCR and immunohistochemistry. Results were correlated with RhoC protein expression data.
In the SUM149 cell line, the caveolin-1 and -2 promoter sites were hypomethylated. A significantly increased expression of caveolin-1 and -2, both at the mRNA and protein level was found in IBC cell lines and in human samples of IBC: caveolin-1 and -2 mRNA were respectively 1.7 (p = 0.02) and 2.2 (p = 0.03) fold more expressed in IBC compared to non IBC and at the protein level, 41.4% of IBC specimens expressed either caveolin-1 or -2, compared to 15.6% of non-IBC specimens (p = 0.03). Furthermore a correlation was found between RhoC protein expression and caveolin-1 (p = 0.1) or caveolin-2 (p = 0.09) or either caveolin-1 or -2 protein expression (p = 0.04).
Although considered a tumour suppressor in breast cancer, we demonstrated overexpression of caveolin-1 and -2 in IBC cell lines and in human samples of IBC, most likely due to hypomethylation of their respective promoters. These results confirm the distinct molecular signature of IBC. Our data further suggest interaction between RhoC GTPase and the caveolins in IBC.
Keywordscaveolin-1 caveolin-2 inflammatory breast cancer methylation RhoC GTPase
Unable to display preview. Download preview PDF.
- 2.Colpaert CG, Vermeulen PB, Benoy I, Soubry A, van Roy F, van Beest P, Goovaerts G, Dirix LY, van Dam P, Fox SB, Harris AL, van Marck EA, 2003. Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression Br J Cancer 88: 718–725CrossRefPubMedGoogle Scholar
- 3.Van der Auwera I, Van Laere SJ, Van den Eynden GG, Benoy I, van Dam P, Colpaert CG, Fox SB, Turley H, Harris AL, Van Marck EA, Vermeulen PB, Dirix LY, 2004. Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification Clin Cancer Res 10: 7965–7971CrossRefPubMedGoogle Scholar
- 13.Cheng JC, Frackelton AR Jr., Bearer EL, Kumar PS, Kannan B, Santos-Moore A, Rifai A, Settleman J, Clark JW, 1995. Changes in tyrosine-phosphorylated p190 and its association with p120 type I and p100 type II rasGAPs during myelomonocytic differentiation of human leukemic cells Cell Growth Differ 6: 139–148PubMedGoogle Scholar
- 19.Marionnet C, Lalou C, Mollier K, Chazal M, Delestaing G, Compan D, Verola O, Vilmer C, Cuminet J, Dubertret L, Basset-Seguin N, 2003. Differential molecular profiling between skin carcinomas reveals four newly reported genes potentially implicated in squamous cell carcinoma development Oncogene 22: 3500–3505CrossRefPubMedGoogle Scholar
- 22.Shinto E, Tsuda H, Matsubara O, Mochizuki H, 2003 [Significance of RhoC expression in terms of invasion and metastasis of colorectal cancer] Nippon Rinsho 7(61 Suppl): 215–219Google Scholar
- 30.Van Laere S, Van der Auwera I, Van den Eynden GG, Fox SB, Bianchi F, Harris AL, van Dam P, van Marck EA, Vermeulen PB, Dirix LY: Distinct molecular signature of inflammatory breast cancer bij cDNA microarray analysis. in Press: Breast Cancer Research and Treatment, 2005Google Scholar
- 31.Van Den Eynden GG, Van Der Auwera I, Van Laere S, Colpaert CG, Van Dam P, Merajver S, Kleer CG, Harris AL, Van Marck EA, Dirix LY, Vermeulen PB, 2004. Validation of a tissue microarray to study differential protein expression in inflammatory and non-inflammatory breast cancer Breast Cancer Res Treat 85: 13–22CrossRefPubMedGoogle Scholar
- 32.van Golen KL, Davies S, Wu ZF, Wang Y, Bucana CD, Root H, Chandrasekharappa S, Strawderman M, Ethier SP, Merajver SD, 1999. A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype Clin Cancer Res 5: 2511–9PubMedGoogle Scholar
- 38.American Joint Committee on Cancer, 2002. AJCC Cancer Staging Manual Sixth Edition. Springer Verlag, New York – Berlin – Heidelberg, p. 221–240Google Scholar
- 40.Davies S, van Golen KL, Hu H, Ethier SP, Merajver S: Identification of Genes Differentially Methylated in Inflammatory Breast Cancer. In: Proceedings of the AACR. AACR 89th Annual Meeting, New Orleans, LA, 1998, pp 259Google Scholar
- 42.Engelman JA, Zhang XL, Lisanti MP, 1999. Sequence and detailed organization of the human caveolin-1 and -2 genes located near the D7S522 locus (7q31.1). Methylation of a CpG island in the 5′ promoter region of the caveolin-1 gene in human breast cancer cell lines FEBS Lett 448: 221–230CrossRefPubMedGoogle Scholar
- 48.Williams TM, Medina F, Badano I, Hazan RB, Hutchinson J, Muller WJ, Chopra NG, Scherer PE, Pestell RG, Lisanti MP, 2004. Caveolin-1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastasis in vivo. Role of Cav-1 in cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion J Biol Chem 279: 51630–51646CrossRefPubMedGoogle Scholar
- 52.Podar K, Shringarpure R, Tai YT, Simoncini M, Sattler M, Ishitsuka K, Richardson PG, Hideshima T, Chauhan D, Anderson KC, 2004. Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib Cancer Res 64: 7500–7506CrossRefPubMedGoogle Scholar
- 53.Lin M, Bao L, Boyanapalli M, Merajver S, van Golen KL: Pancreatic cancer cell motility is controlled through interaction of RhoC GTPase and caveolin-1. In: Proceedings of the AACR. AACR 95th Annual Meeting, Orlando, FL, 2004, S.143Google Scholar
- 54.Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D, 2000. Molecular portraits of human breast tumours Nature 406: 747–752CrossRefPubMedGoogle Scholar
- 65.Liu J, Razani B, Tang S, Terman BI, Ware JA, Lisanti MP, 1999. Angiogenesis activators and inhibitors differentially regulate caveolin-1 expression and caveolae formation in vascular endothelial cells. Angiogenesis inhibitors block vascular endothelial growth factor-induced down-regulation of caveolin-1 J Biol Chem 274: 15781–15785CrossRefPubMedGoogle Scholar